-
Viral vIRD Control of RIPK3 and Inflammation
2026-08-19
Liu et al. identified a cowpox virus and orthopoxvirus factor, termed vIRD, that recruits host SCF machinery to drive ubiquitination and proteasomal degradation of RIPK3. Genetic and mouse infection experiments showed that this immune-evasion mechanism shapes necroptosis, inflammation, viral replication, and mortality in a RIPK3- and MLKL-dependent manner.
-
HyperScript RT SuperMix for qPCR Workflow
2026-08-19
Build a robust two-step qRT-PCR workflow for macrophage signaling, sepsis-induced acute lung injury, and low-input RNA samples. HyperScript™ RT SuperMix for qPCR combines a thermostable HyperScript Reverse Transcriptase with mixed priming to support reproducible cDNA synthesis for qPCR when RNA structure or limited sample volume is a concern.
-
COX-2, Ischemia, and Revascularization After Venom Injury
2026-08-18
This study identifies a time-dependent role for cyclooxygenase-2 (COX-2) in skeletal muscle injury caused by Bothrops asper venom: early COX-2 activity helps preserve vascular integrity, whereas early inhibition later increases proangiogenic signaling. The findings show why temporal control, rather than blanket suppression, is essential when interpreting COX-2 pathway modulation in muscle ischemia and repair.
-
(-)-Blebbistatin in Cardiac Mechanobiology
2026-08-18
Explore how (-)-Blebbistatin, a reversible non-muscle myosin II inhibitor, can be paired with transparent multimodal cardiac bioelectronics to connect actin-myosin remodeling with electrical and metabolic physiology.
-
Y-27632: Practical ROCK Inhibitor Workflow
2026-08-17
Y-27632 provides a reversible, ATP-competitive way to perturb ROCK1 and ROCK2 activity in biochemical and cell-based assays, helping researchers examine cytoskeletal organization and ROCK signaling pathway research. Use it as an experimental pathway-perturbation tool rather than as a universal viability enhancer, clinical agent, or substitute for matched controls and assay-specific optimization.
-
Lumiracoxib: Designing Better COX-2 Assays
2026-08-17
Lumiracoxib is a selective COX-2 inhibitor that can do more than suppress prostaglandin production. This article shows how to use its temporal pharmacology, chemical properties, and vascular-repair findings to design more interpretable inflammation and revascularization assays.
-
WM-8014: From KAT6A Mechanism to Translation
2026-08-16
WM-8014 connects competitive KAT6A/B inhibition with cell-cycle arrest, senescence, and oncogene-driven overproliferation. This thought-leadership guide shows how to use the compound as a mechanistic probe while accounting for selectivity, formulation, model maturity, and translational limitations.
-
Bestatin (Ubenimex): From Active Site to Translation
2026-08-15
Bestatin (Ubenimex) is more than a catalog inhibitor: its zinc-enzyme structural biology, selectivity profile, and cell-based precedents make it a useful bridge between aminopeptidase mechanism and translational research. This article presents a strategy for pairing biochemical validation, aminopeptidase activity measurement, apoptosis assays, and multidrug resistance research without overextending preclinical evidence.
-
LDH Cytotoxicity Assay Kit: Practical Workflow
2026-08-14
The LDH Cytotoxicity Assay Kit provides a non-radioactive approach for measuring cell membrane damage through LDH released into culture medium. It is suitable for endpoint cytotoxicity and cell damage quantification, but LDH release alone should not be used to identify apoptosis or establish a specific death mechanism.
-
Lamotrigine: Sodium Channel Research Guide
2026-08-14
Lamotrigine is a high-purity research compound characterized as a sodium channel blocker and serotonin-pathway inhibitor. This guide defines its chemical benchmarks, assay limits, cardiac and epilepsy research uses, and practical handling parameters for SKU B2249.
-
c-Myc Peptide: Mechanism-First Assay Guide
2026-08-13
Explore how the c-Myc tag peptide functions as a precise epitope-competition reagent for immunoassays. This guide connects assay design with transcription-factor biology while distinguishing validated product uses from emerging cross-domain interpretations.
-
Penicillin G Sodium in Barrier-Model Workflows
2026-08-13
Learn how Penicillin G Sodium can sharpen Gram-positive infection models, control culture contamination, and help separate bacterial-load effects from endotoxin-driven barrier injury. This workflow-focused guide pairs product handling with the P65/TNF-α/MLCK/ZO-1 framework reported in a recent intestinal-barrier study.
-
Alternariol (AOH) for Mycotoxin Research
2026-08-12
Alternariol (AOH) is a defined tool for connecting foodborne toxin exposure with CYP metabolism, apoptosis, and hepatic stellate-cell activation. This workflow shows how to prepare C5061, separate cytotoxicity from fibrosis-related phenotypes, and build orthogonal assays for reproducible mycotoxin research.
-
Intermittent Stress, F-Actin, and YAP Mechanomemory
2026-08-12
Rashid and colleagues show that brief intermittent integrin-mediated stresses can produce a mechanomemory response comparable to prolonged loading, with increased cytoplasmic F-actin accompanying YAP nuclear translocation and Ctgf expression. The study identifies stress timing and actomyosin-dependent cytoskeletal remodeling as important variables for interpreting cellular mechanotransduction.
-
Amiloride (MK-870): Workflow for Ion Transport
2026-08-11
Amiloride (MK-870) provides a reversible way to interrogate epithelial sodium transport, PC2-linked signaling, and selected uptake phenotypes. This workflow also shows how to use it as a carefully controlled perturbation when extending endoplasmic-reticulum-targeted immunoliposome studies into cellular uptake and antigen-presentation assays.